fa عوامل مرتبط با پیامدهای بالینی کووید-19 در بیماران مبتلا به مولتیپل اسکلروزیس در استان مازندران: یک گزارش کوتاه نورولوژی(بیماریهای مغز و اعصاب) Neurology گزارش کوتاه Brief Report <span style="line-height:2;"><span style="font-size:12pt"><span style="direction:rtl"><span style="unicode-bidi:embed"><span style="font-family:&quot;Times New Roman&quot;,&quot;serif&quot;"><span lang="FA" style="font-family:&quot;B Koodak&quot;"><span style="color:black"><span style="letter-spacing:-.1pt">سابقه</span></span></span><span lang="AR-SA" style="font-family:&quot;B Koodak&quot;"><span style="color:black"><span style="letter-spacing:-.1pt"> و هدف:</span></span></span> <span lang="AR-SA" style="font-family:&quot;B Zar&quot;"><span style="letter-spacing:-.2pt">ﺑﺎ ﺗﻮﺟﻪ ﺑﻪ ﻧﺮﺥ ﺑﺎﻻﯼ ﻣﺮﮒ ﻭ ﻣﯿﺮ ﺑﺮﺍﯼ ﻋﻔﻮﻧﺖ ﻭیﺮﻭﺳﯽ ﮐﻮﻭیﺪ19-، ﻣﻄﺎﻟﻌﻪ ﺣﺎﺿﺮ ﺑﺎ ﻫﺪﻑ ﺑﺮﺭﺳﯽ ﭘﯿﺎﻣﺪﻫﺎﯼ ﺑﺎﻟﯿﻨﯽ ﻋﻔﻮﻧﺖ ﮐﻮﻭیﺪ19- ﺩﺭ ﺑﯿﻤﺎﺭﺍﻥ ﻣﻮﻟﺘﯿﭙﻞ ﺍﺳﮑﻠﺮﻭﺯیﺲ، ﺍﻧﺠﺎﻡ پذیرفت</span></span><span lang="FA" style="font-family:&quot;B Zar&quot;"><span style="color:#0e101a"></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="direction:rtl"><span style="unicode-bidi:embed"><span style="font-family:&quot;Times New Roman&quot;,&quot;serif&quot;"><span lang="AR-SA" style="font-family:&quot;B Koodak&quot;"><span style="color:black"><span style="letter-spacing:-.1pt">مواد و روش</span></span></span><span lang="FA" style="font-family:&quot;B Zar&quot;"><span style="color:black"><span style="letter-spacing:-.1pt">‌</span></span></span><span lang="AR-SA" style="font-family:&quot;B Koodak&quot;"><span style="color:black"><span style="letter-spacing:-.1pt">ها:</span></span></span> <span lang="FA" style="font-family:&quot;B Zar&quot;">در این مطالعه توصیفی- تحلیلی، ﺑﯿﻤﺎﺭﺍﻥ که در طی شرح حال گیری اولیه ﺩﺭ ﺑﺎﺯﻩ ﺯﻣﺎﻧﯽ ﺍﺳﻔﻨﺪ 98 ﺍﻟﯽ ﺍﺳﻔﻨﺪ 99 پاسخگو بودند، ﻭﺍﺭﺩ ﻣﻄﺎﻟﻌﻪ ﺷﺪﻧﺪ. ﮐﻠﯿﻪ ﺑﯿﻤﺎﺭﺍﻥ ﺍﻡ ﺍﺱ ﻭ ﺑﺎﻟﻎ ﺑﺎ ﺳﻦ بیش‌تر ﺍﺯ 18 ﺳﺎﻝ ﺑﺎ ﺍﺳﺘﻔﺎﺩﻩ ﺍﺯ ﺭﻭﺵ ﺳﺮﺷﻤﺎﺭﯼ، ﺍﻧﺘﺨﺎﺏ ﺷﺪﻧﺪ .ﻣﺸﺨﺼﺎﺕ ﺩﻣﻮﮔﺮﺍﻓﯿﮏ، ﺑﯿﻤﺎﺭﯼﻫﺎﯼ ﺯﻣﯿﻨﻪﺍﯼ، ﺩﺍﺭﻭﻫﺎﯼ ﻣﺼﺮﻓﯽ ﻭ ﺗﻈﺎﻫﺮﺍﺕ ﺑﺎﻟﯿﻨﯽ آن ها ﺛﺒﺖ ﺷﺪ. ﻣﻮﺍﺭﺩ ﺑﺴﺘﺮﯼ شده در مرکز درمانی ﺑﺮ ﺍﺳﺎس ﭘﺮﻭﻧﺪﻩ ﺍﻟﮑﺘﺮﻭنیکی ﺑﻪ ﺍﻃﻼﻋﺎﺕ ﺩﺳﺘﺮﺳﯽ ﺣﺎﺻﻞ ﺷﺪ. سطح معنی‌داری کم‌تر از ۰</span>٫<span lang="FA" style="font-family:&quot;B Zar&quot;">۰۵ در نظر گرفته شد.</span><span lang="FA" style="font-family:&quot;B Zar&quot;"><span style="color:black"><span style="letter-spacing:-.1pt"></span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="direction:rtl"><span style="unicode-bidi:embed"><span style="font-family:&quot;Times New Roman&quot;,&quot;serif&quot;"><span lang="AR-SA" style="font-family:&quot;B Koodak&quot;"><span style="color:black"><span style="letter-spacing:-.2pt">یافته</span></span></span><span lang="FA" style="font-family:&quot;B Zar&quot;"><span style="color:black"><span style="letter-spacing:-.2pt">‌</span></span></span><span lang="AR-SA" style="font-family:&quot;B Koodak&quot;"><span style="color:black"><span style="letter-spacing:-.2pt">ها:</span></span></span> <span lang="AR-SA" style="font-family:&quot;B Zar&quot;">ﺩﺭ ﺍیﻦ ﻣﻄﺎﻟﻌﻪ ﮐﻪ 618 ﻧﻔﺮ ﺍﺯ ﺑﯿﻤﺎﺭﺍﻥ ﺍﻡ ﺍﺱ ﺍﺳﺘﺎﻥ ﻣﺎﺯﻧﺪﺭﺍﻥ ﺑﺮﺭﺳﯽ ﺷﺪﻧﺪ و ﺗﻌﺪﺍﺩ ﻣﻮﺍﺭﺩ ﺍﺑﺘﻼ ﺑﻪ ﮐﺮﻭﻧﺎ ﺩﺭ ﺯﻧﺎﻥ ﻧﺴﺒﺖ ﺑﻪ ﻣﺮﺩﺍﻥ ﺑﯿﺶﺗﺮ ﺑﻮﺩ. میانگین ﺷﺎﺧﺺ ﺗﻮﺩﻩ ﺑﺪﻧﯽ و ﺩﺍﺭﻭﻫﺎﯼ ﺍﻡ ﺍﺱ ﻭ ﻭﺿﻌﯿﺖ ﺑﺴﺘﺮﯼ ﺷﺪﻥ و ﻋﻼﺋﻢ ﺑﺎﻟﯿﻨﯽ در ﺍﻓﺮﺍﺩ مبتلا ﺑﺎ ﻭﺿﻌﯿﺖ ﺑﺴﺘﺮﯼ ﺍﺭﺗﺒﺎﻁ ﻣﻌﻨﯽﺩﺍﺭﯼ بیان ﻧﺸﺪ. ﻣﯿﺎﻧﮕﯿﻦ </span><span dir="LTR" style="font-size:10.0pt">EDSS</span><span style="font-family:&quot;B Zar&quot;"> ﻗﺒﻞ ﺍﺯ ﮐﺮﻭﻧﺎ ﺩﺭ ﺩﻭ ﮔﺮﻭﻩ ﺑﺴﺘﺮﯼ ﺷﺪﻩ ﻭ ﺑﺴﺘﺮﯼ ﻧﺸﺪﻩ ﺍﺧﺘﻼﻑ ﻣﻌﻨﯽﺩﺍﺭﯼ ﻭﺟﻮﺩ ﻧﺪﺍﺭﺩ.</span><span lang="FA" style="font-family:&quot;B Zar&quot;"><span style="color:black"></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="direction:rtl"><span style="unicode-bidi:embed"><span style="font-family:&quot;Times New Roman&quot;,&quot;serif&quot;"><span lang="AR-SA" style="font-family:&quot;B Koodak&quot;"><span style="color:black"><span style="letter-spacing:-.2pt">استنتاج:</span></span></span> <span lang="FA" style="font-family:&quot;B Zar&quot;">ﺟﻨﺴﯿﺖ ﺧﺎﻧﻢ و فشارخون بالا ﺍﺯ ﺟﻤﻠﻪ ﻓﺎﮐﺘﻮﺭهای اصلیﮐﻪ ﺷﺎﻧﺲ ﺍﺑﺘﻼ ﺑﻪ ﮐﻮﻭیﺪ - 19 ﺭﺍ ﺩﺭ ﺑﯿﻤﺎﺭﺍﻥ ﻣﺒﺘﻼ ﺑﻪ ﺍﻡ ﺍﺱ ﺍﻓﺰﺍیﺶ ﻣﯽﺩﻫﺪ. ﻧﻮﻉ ﺩﺍﺭﻭﻫﺎﯼ ﺗﻌﺪیﻞ ﮐﻨﻨﺪﻩ ﺳﯿﺴﺘﻢ ﺍیﻤﻨﯽ ﺩﺭ ﺍﻡ ﺍﺱ ﺩﺭ ﺑﺮﻭﺯ ﮐﻮﻭیﺪ - 19 ﺩﺭ ﺍیﻦ ﺟﻤﻌﯿﺖ ﺍﺭﺗﺒﺎﻁ ﻣﺸﺨﺼﯽ ﺭﺍ ﻧﺸﺎﻥ ﻧﺪﺍﺩﻧﺪ. این نتایج می‌تواند در طراحی راهکارهای پیشگیرانه و اولویت‌بندی واکسیناسیون در این جمعیت آسیب‌پذیر، مورد استفاده قرار گیرد. انجام مطالعات آینده‌نگر با حجم نمونه بیش‌تر برای تأیید این یافته‌ها توصیه می‌شود.</span><span lang="AR-SA" style="font-family:&quot;B Zar&quot;"><span style="color:black"><span style="letter-spacing:-.2pt"></span></span></span></span></span></span></span></span><br> &nbsp; <span style="line-height:2;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,&quot;serif&quot;"><b><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;"><span style="letter-spacing:-.2pt">Background and purpose:</span></span></span></b> <span style="font-size:10.0pt"><span style="background:white">Given the high mortality associated with COVID-19 infection, this study aimed to investigate the clinical outcomes of COVID-19 infection in patients with multiple sclerosis (MS).</span></span><span style="font-size:10.0pt"><span style="line-height:150%"></span></span></span></span><br> <span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,&quot;serif&quot;"><b><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">Materials and methods:</span></span></b><b> </b><span style="font-size:10.0pt"><span style="background:white">Patients who provided a response during the initial history-taking process between February 2020 and February 2021 were included in the study. All adult patients with MS aged 18 years or older were identified using census sampling. Demographic characteristics, underlying medical conditions, medications, and clinical manifestations were recorded. Information on patients hospitalised at the medical centre was obtained from electronic medical records. A p-value of less than 0.05 was considered statistically significant.</span></span><span style="font-size:10.0pt"><span style="letter-spacing:-.1pt"></span></span></span></span><br> <span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,&quot;serif&quot;"><b><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">Results:</span></span></b><b> </b><span style="font-size:10.0pt"><span style="background:white">The study included 618 patients with MS from Mazandaran Province. The incidence of COVID-19 infection was higher among women than men. No significant associations were found between hospitalisation and factors such as mean body mass index (BMI), use of MS immunomodulatory medications, or other clinical symptoms. Furthermore, no significant difference was observed in pre-COVID-19 scores on the Expanded Disability Status Scale (EDSS) between hospitalised and non-hospitalised patients.</span></span><span lang="EN" style="font-size:10.0pt"><span style="line-height:150%"></span></span></span></span><br> <span style="font-size:12pt"><span style="vertical-align:top"><span style="font-family:&quot;Times New Roman&quot;,&quot;serif&quot;"><b><span style="font-size:10.0pt"><span style="font-family:&quot;Arial&quot;,&quot;sans-serif&quot;">Conclusion:</span></span></b><span style="font-size:10.0pt"><span style="background:white"> Female sex and hypertension were associated with an increased risk of COVID-19 infection among patients with MS. No clear association was observed between the specific types of immunomodulatory medications used to treat MS and the occurrence of COVID-19 in this population. These findings may help inform preventive strategies and vaccination prioritisation for this potentially vulnerable population. Prospective studies with larger sample sizes are recommended to confirm these findings.</span></span><i><span style="font-size:10.0pt"><span style="color:black"></span></span></i></span></span></span></span><br> &nbsp; ﮐﻮﻭیﺪ19-, ﻣﻮﻟﺘﯿﭙﻞ ﺍﺳﮑﻠﺮﻭﺯیﺲ, پیامدهای بالینی, ریسک فاکتور, پروگنوز covid-19, multiple sclerosis, clinical outcomes, risk factors, prognosis 144 150 http://jmums.mazums.ac.ir/browse.php?a_code=A-10-9959-4&slc_lang=fa&sid=1 Amir Hoseein Mesgar امیرحسین مسگر amirhoseinmesgar@yahoo.com 1003194753284600190820 1003194753284600190820 No Pharmacy Student, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Ramsar, Iran دانشجوی داروسازی، گروه داروسازی، دانشکده داروسازی، دانشگاه علوم پزشکی مازندران، رامسر، ایران Seyed Mohammad Baghbanian سید محمد باغبانیان mohammadbaghbanian@gmail.com 1003194753284600190821 1003194753284600190821 No Associate Professor, Department of Neurology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran دانشیار، گروه مغز و اعصاب، دانشکده پزشکی، دانشگاه علوم پزشکی مازندران، ساری، ایران. Monireh Ghazaeian منیره غزائی یان ghazaeianm@gmail.com 1003194753284600190822 1003194753284600190822 Yes Assistant Professor, Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran استادیار، گروه داروسازی بالینی، دانشکده داروسازی، دانشگاه علوم پزشکی مازندران، ساری، ایران